Hansa Biopharma AB has announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function in highly sensitised adult kidney transplant patients with positive crossmatch against a deceased donor, versus the control arm.
The trial saw patient retention in excess of 90%, and met the primary endpoint of kidney function at 12 months as measured by mean estimated glomerular filtration rate (eGFR) with a p-value of <0.0001. The company plans to submit a BLA under the accelerated approval pathway to the US Food and Drug Administration (FDA) by the end of 2025.
Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “We are excited to share the data from the US ConfIdeS trial, which clearly shows the clinically meaningful benefit of imlifidase in kidney transplantation of highly sensitized patients, and the role it can play in shaping future standard of care. These results corroborate the existing clinical and real-world evidence of the use of imlifidase as an effective desensitization therapy in kidney transplantation. We look forward to sharing this body of data with the FDA in our mission to bring this medicine to these patients who today have very limited options. I would like to thank all the patients, their families, as well as the investigators and the site staff who continue to participate in the trial.”
Robert Montgomery, New York University Langone Health, said: “There have been few major breakthroughs in desensitisation strategies in kidney transplantation for the last 30 years. The unmet need remains high for kidney transplant patients who are considered highly sensitised, with many remaining on the wait list with little to no hope of receiving a suitable match for transplantation. The result from the US ConfIdeS trial are highly encouraging and demonstrate the significant potential for imlifidase to transform standard of care for highly sensitised kidney transplant patients.”
A key secondary outcome relating to dialysis independence at 12 months was also statistically significant in favor of imlifidase. Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience.
Full results from the trial will be submitted to a medical congress in 2026.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
